Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschr&auml;nkter Haftung

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Rolf Gericke

Norbert Beier

Manfred Baumgarth

Rolf Bergmann

Dieter Dorsch

Klaus-Otto Minck

Werner Mederski

Ingeborg Lues

Florian Lang

Jacques De Peyer

Markus Klein

Christos Tsaklakidis

Helmut Wahlig

Lars Thore Burgdorf

Inge Lues

Hanns Wurziger

Bertram Cezanne

Gunther Hausler

Elvira Dingeldein

Thomas Fuchss

Horst Juraszyk

Werner Rogalski

Walter Hameister

Hartmut Greiner

Rudolf Gottschlich

Claus J Schmitges

Klaus Otto Minck

Jurgen Seubert

Karl Lang

Michael Gassen

Henning B&ouml;ttcher

Ulrich Graedler

Ralf M Devant

Oliver Poeschke

Jurgen Harting

Philipp Lang

Wighard Strehlow

Phillipp Lang

De Peyer

Manfred Haumgarth

Helga Drosdat

Bernhard Ladstetter

Hans Markus Bender

Novel heterocyclic compounds of the formula (I), in which R, D, W, T and T' have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Heterocyclic carbonyl compounds

The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.

SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas

Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R, R, R, R, R, Rand Rhave the meanings indicated in claim, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases.

Difluorophenyldiacylhydrazide derivatives

Novel compounds of the formula I, in which X, Y, R, R', R, R, R, R, R, R, R, R, R, Rand n have the meanings indicated in Patent Claim, are suitable as antidiabetics 

3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors

Novel aminoindazolylurea derivatives of the formula I (I), in which R, R, R, R, R, X and Y have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Aminoindazolylurea derivatives

Novel compounds of the formula (I), in which W, T, R, R, R, R, Rand Rhave the meanings indicated in Patent Claim (), are suitable as antidiabetics. 

3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes

Novel compounds of the formula I (I), in which R, R, R, R, R, R, R, R, R, R, R, R, R, R, Q, W, X and Z have the meanings indicated in Patent Claimare suitable as antidiabetics.

Benzimidazole derivatives

Novel compounds of the formula (I), in which X, Y, R, R, R, R, R, R, R, R, R, Rand n have the meanings indicated in patent claim, are suitable as antidiabetics. 

Indolizine derivatives and the use thereof as antidiabetics

The invention relates to novel indazole derivatives as cited in claim, which are inhibitors of CHK1, CHK2 and SGK kinases and can be used to treat cancer and other diseases.

Indazole-heteroaryl derivatives

Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type. 

3-aminoindazoles

Novel mandelic hydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Mandelic hydrazides

Novel acyl hydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type. 

Acyl hydrazines as kinase inhibitors, in particular for SGK

Novel ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acetohydrazides of the formula (I), in which R-Rhave the meanings indicated in claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides

The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: Rand Rindependently of one another represent H, OH, OA, OAc or methyl; R, R, R, R, R, R, Rand Rindependently of one another represent H, OH, OA, OAc, OCF, Hal, NO, CF, A, CN, OSOCH, SOCH, NH, or COOH; Rrepresents H or CH; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH, CHCH, OCHor &#x2014;CH(OH)&#x2014; and Hal represents F, Cl, Br or I. 

Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction

Sulfonyloxazoleamines

Growing community of inventors

Seeheim-Jugenheim, Germany

Rolf Gericke